Disease modification in inflammatory skin disorders: opportunities and challenges
A comprehensive review from our founder Prof. Thomas Bieber
15. August 2023
Menu
A comprehensive review from our founder Prof. Thomas Bieber
Our CK-CARE Biobank received the SBP VITA Label Building up a proper Governance through accountable mechanisms is key to foster trustworthiness and the prerequisite for the appropriate use of biological resources. Our CK-CARE Biobank has recently been awarded by the Swiss Biobanking Platform (SBP) with the VITA Label, which demonstrates compliance with the applicable legal and ethical framework. This labeling approach is part of our long-term strategy to strengthen biobanking
Davos BioSciences AG achieved the official OPTIMA label of the Swiss Biobanking Platform for its biobank infrastructure as of 30.05.2022. This is another important step for Davos BioSciences AG and CK-CARE. The label attests to the full implementation of a QM system. The OPTIMA-Label confirms: “Compliance with the Good Biobanking Practices; in particular OECD Best practice guidelines for biological resource centres (2007), ISBER Best practices (2018) and IARC Common minimum
Our founder, Prof. Thomas Bieber, published an important contribution in the treatment of AD: Atopic dermatitis (AD) is a common chronic inflammatory skin disease with a complex pathophysiology that underlies a wide spectrum of clinical phenotypes. AD remains challenging to treat owing to the limited response to available therapies. However, recent advances in understanding of disease mechanisms have led to the discovery of novel potential therapeutic targets and drug candidates.
DBS achieved a milestone by getting the NORMA label of Swiss Biobanking Plattform for its infrastructure. The NORMA label confirms: “Compliance with professional standards (e.g. ISO 20387:2018) is essential to perform our daily biobanking activities according to Good Biobanking Practices. After having successfully achieved the Vita label, our Biobank Infrastructure was recently awarded with the next step Norma label which demonstrates compliance with the Swiss Biobanking Platform (SBP) requirements for standardization
On April 21th, our new Axioscan slide scanner was installed. We look forward to acquire histological data in brightfield and fluorescence.
we could proudly start first measurements of samples and look forward to the results
DBS signed a first contract with a key player in dermatology treatments. DBS will measure biological parameters in samples from patients with atopic dermatitis and contribute novel insights in the pathogenesis and the treatment of the disease.
The common ragweed (Ambrosia artemisiifolia) produces pollen which can trigger strong reactions such as asthma. A research team headed by Prof. Claudia Traidl-Hoffmann, who is on the Board of Directors of CK-CARE (Christine Kühne – Center for Allergy Research and Education), has shown that what was previously known as the principal allergen only has such a strong allergenic effect when combined with the substance adenosine, which is also present in